SCHEMBL3072382

SCHEMBL3072382

Cc1ccc(Cc2cccc(CSc3[c]cccc3)c2)cc1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.35
RAB9A P51151 2/20 0.35
NPC1 O15118 1/20 0.35
ALDH1A1 P00352 4/20 0.34
CYP1A2 P05177 3/20 0.34
CYP2C19 P33261 3/20 0.34
HPGD P15428 2/20 0.34
HTT P42858 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
CYP2C9 P11712 2/20 0.34
MEN1 O00255 2/20 0.34
CYP3A4 P08684 2/20 0.34
KMT2A Q03164 2/20 0.34
SLC5A2 P31639 1/20 0.34
MAPT P10636 2/20 0.33
BCHE P06276 1/20 0.33
ACHE P22303 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
KCNH2 Q12809 1/20 0.33
MAPK1 P28482 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3084401 0.90 TP53 (0.36) LMNARAB9ANPC1CYP1A2CYP2C19
SCHEMBL3095270 0.86 SLC6A4 (0.38) LMNARAB9ANPC1ALDH1A1CYP1A2
SCHEMBL3082324 0.85 TOP2A (0.37) LMNARAB9ANPC1ALDH1A1CYP1A2
SCHEMBL3097410 0.85 LTA4H (0.50) LMNARAB9ANPC1ALDH1A1CYP1A2
SCHEMBL4302 0.75 POLB (0.44) RAB9ANPC1ALDH1A1CYP1A2HTT
SCHEMBL15694827 0.75 CALM1 (0.55) LMNARAB9ANPC1ALDH1A1CYP2C19
SCHEMBL3091274 0.73 TP53 (0.31) LMNATP53
SCHEMBL9934897 0.72 ALDH1A1 (0.39) LMNAALDH1A1CYP1A2CYP2C19HPGD
SCHEMBL29137646 0.71 MAPT (0.43) LMNARAB9ANPC1ALDH1A1CYP1A2
SCHEMBL6353303 0.70 IDO1 (0.37) LMNARAB9ANPC1ALDH1A1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8207134-B2 Fused ring spiroketal derivative and use thereof as anti-diabetic drug CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2012-06-26 US disclosed
US-20100234609-A1 FUSED RING SPIROKETAL DERIVATIVE AND USE THEREOF AS ANTI-DIABETIC DRUG CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2010-09-16 US disclosed
EP-2048152-A1 FUSED RING SPIROKETAL DERIVATIVE AND USE THEREOF AS DRUG FOR TREATING DIABETES CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2009-04-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100234609-A1 FUSED RING SPIROKETAL DERIVATIVE AND USE THEREOF AS ANTI-DIABETIC DRUG REN, WNK1, GCKR LMNA 2203/4885RAB9A 1447/4885NPC1 2342/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.